STOCK TITAN
  1. Home
  2. News
  3. BCDA

BioCardia Inc. - BCDA STOCK NEWS

IMPACT
SENTIMENT
BCDA : Nasdaq
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
IMPACT
SENTIMENT
BCDA : Nasdaq
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
offering
IMPACT
SENTIMENT
BCDA : Nasdaq
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
fda approval
IMPACT
SENTIMENT
BCDA : Nasdaq
BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
earnings
IMPACT
SENTIMENT
BCDA : Nasdaq
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023
conferences earnings
IMPACT
SENTIMENT
BCDA : Nasdaq
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
clinical trial
IMPACT
SENTIMENT
BCDA : Nasdaq
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
IMPACT
SENTIMENT
BCDA : Nasdaq
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
clinical trial
IMPACT
SENTIMENT
BCDA : Nasdaq
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
earnings
IMPACT
SENTIMENT
BCDA : Nasdaq
BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
conferences earnings
Stock BCDA logo
BioCardia Inc.

Nasdaq:BCDA

BCDA Rankings

#7047 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BCDA Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
San Carlos

About BCDA

we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.